FY2025 EPS Estimate for Cytokinetics Decreased by Analyst

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Cytokinetics in a research note issued on Monday, December 22nd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of ($5.78) per share for the year, down from their prior forecast of ($5.75). HC Wainwright currently has a “Buy” rating and a $136.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. HC Wainwright also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.75) EPS.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to the consensus estimate of $6.05 million. Cytokinetics’s revenue for the quarter was up 318.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.36) earnings per share.

A number of other research analysts also recently issued reports on CYTK. Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research note on Monday. Needham & Company LLC lifted their price target on shares of Cytokinetics from $72.00 to $84.00 and gave the company a “buy” rating in a report on Monday. Leerink Partners set a $83.00 price target on shares of Cytokinetics in a research report on Monday. Bank of America increased their price objective on shares of Cytokinetics from $52.00 to $56.00 and gave the stock a “neutral” rating in a research note on Thursday, October 2nd. Finally, Stifel Nicolaus lifted their target price on shares of Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $83.61.

Cytokinetics Stock Up 0.9%

Shares of CYTK opened at $63.86 on Wednesday. The business has a 50-day simple moving average of $62.99 and a two-hundred day simple moving average of $49.31. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $70.98. The stock has a market cap of $7.81 billion, a price-to-earnings ratio of -10.15 and a beta of 0.58.

Insider Activity

In related news, Director Edward M. Md Kaye sold 28,064 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $66.72, for a total transaction of $1,872,430.08. Following the completion of the transaction, the director directly owned 9,977 shares of the company’s stock, valued at approximately $665,665.44. This trade represents a 73.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director John T. Henderson sold 8,750 shares of Cytokinetics stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $63.90, for a total transaction of $559,125.00. Following the completion of the sale, the director owned 74,578 shares in the company, valued at approximately $4,765,534.20. This represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 168,494 shares of company stock valued at $10,811,018 in the last quarter. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP boosted its position in shares of Cytokinetics by 676.1% during the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock valued at $90,559,000 after acquiring an additional 1,435,422 shares during the last quarter. Norges Bank purchased a new stake in Cytokinetics during the second quarter valued at $39,122,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lifted its position in Cytokinetics by 571.2% during the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 1,082,563 shares of the biopharmaceutical company’s stock valued at $35,768,000 after purchasing an additional 921,278 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new position in shares of Cytokinetics in the 1st quarter worth $34,510,000. Finally, Deep Track Capital LP grew its stake in shares of Cytokinetics by 17.8% in the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after buying an additional 650,000 shares in the last quarter.

Key Stores Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approval of Myqorzo (aficamten) turns Cytokinetics into a commercial‑stage cardiology biotech and establishes a new revenue runway — a principal driver of investor enthusiasm. Article Title
• Positive Sentiment: Multiple brokers raised price targets or reiterated Buy/Outperform views (examples: Citizens/JMP raised its PT to $88; Morgan Stanley maintained an overweight), supporting further upside expectations. Article Title
• Positive Sentiment: Unusually high call‑option volume suggests traders are positioning for additional near‑term upside. Article Title
• Positive Sentiment: Institutional accumulation reported in recent quarters (new and increased stakes by several funds) provides a supportive ownership base for the rally. Article Title
• Neutral Sentiment: Needham and other brokers reiterated positive ratings (Needham maintained its Buy) — supportive but largely reaffirmative rather than new catalysts. Article Title
• Neutral Sentiment: Reported short‑interest data in December shows zero shares (likely a reporting/data anomaly), so short‑interest signals are currently uninformative.
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at about $66.14 (Dec. 22), trimming his stake ~38% — a potential near‑term negative for sentiment. SEC Filing
• Negative Sentiment: HC Wainwright trimmed Q4 and FY2025 EPS forecasts slightly (small downward revisions to losses per share), signaling modestly weaker near‑term profitability expectations despite maintaining a Buy and a $136 target. Article Title

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.